Lonza Group AG stock (CH0013841017): Q1 2026 results confirm full-year guidance as CDMO leader eyes growth in biologics and cell & gene therapies

Lonza Group AG reported Q1 2026 earnings that confirmed its full-year guidance, highlighting robust growth in biologics and cell & gene therapies while maintaining its position as a leading contract development and manufacturing organization for the global healthcare industry.

Lonza Group AG has reported its Q1 2026 earnings, confirming its full-year guidance and showcasing strong operational execution across its key business segments. The company emphasized robust growth in its biologics and cell & gene therapy businesses, which are central to its strategy as the world’s largest contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotech industries. The results come amid continued demand for outsourced drug development and manufacturing, particularly for complex biologics and advanced therapies.

Lonza’s Q1 2026 performance underpins its full-year outlook, which management reiterated on the earnings call. The company highlighted solid order intake and capacity utilization across its global network of manufacturing sites, supporting expectations for continued revenue growth and margin expansion in 2026. Lonza also pointed to ongoing investments in biologics and cell & gene capabilities as key drivers of long?term value, aligning with broader industry trends toward more complex, high?value therapies.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza Group AG
• Sector/industry: Biotechnology & medical research / contract development and manufacturing organization (CDMO)
• Headquarters/country: Basel, Switzerland
• Core markets: Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and other international markets
• Key revenue drivers: Biologics, small molecules, cell & gene therapies, and capsules & health ingredients
• Home exchange/listing venue: SIX Swiss Exchange (ticker: LONN)
• Trading currency: Swiss franc (CHF)

Lonza Group AG: core business model

Lonza Group AG operates as a global contract development and manufacturing organization, providing end?to?end services for pharmaceutical, biotech, and nutrition customers. The company supports clients from early?stage development through commercial manufacturing, offering expertise in small molecules, biologics, cell & gene therapies, and capsules & health ingredients. Lonza’s business model is built on long?term supply agreements and technology partnerships, which help secure stable revenue streams and deepen customer relationships.

Lonza’s global footprint spans five continents, with manufacturing and development sites in Europe, North America, and Asia. This geographic diversification allows the company to serve multinational pharmaceutical and biotech firms while mitigating regional supply?chain risks. Lonza also emphasizes innovation and process optimization, investing in advanced manufacturing technologies and digital tools to improve efficiency and quality for its clients.

Main revenue and product drivers for Lonza Group AG

The biologics segment is one of Lonza’s primary growth engines, driven by rising demand for monoclonal antibodies, recombinant proteins, and other complex biologic drugs. Lonza’s large?scale biologics manufacturing capacity, including single?use and continuous?processing platforms, positions it as a preferred partner for global biopharma companies. The company has also expanded its biologics footprint in recent years, adding capacity in key regions such as the United States and Europe.

Cell & gene therapies represent another high?growth area for Lonza, reflecting the broader industry shift toward personalized and regenerative medicines. Lonza offers viral vector manufacturing, cell therapy development, and related services that support clinical and commercial?scale production. In addition, the small molecules and capsules & health ingredients segments contribute steady revenue, serving both traditional pharmaceutical and consumer health markets. Together, these segments underpin Lonza’s diversified revenue base and its ability to capture value across the healthcare value chain.

Conclusion

Lonza Group AG’s Q1 2026 results reinforce its position as a leading CDMO with strong growth prospects in biologics and cell & gene therapies. The company’s diversified business model, global manufacturing network, and focus on high?value segments provide a solid foundation for long?term performance. However, investors should remain mindful of industry?wide risks such as regulatory scrutiny, pricing pressures, and capital?intensive expansion projects.

For US investors, Lonza offers exposure to the global healthcare outsourcing market through a liquid listing on the SIX Swiss Exchange. The stock’s valuation, growth trajectory, and dividend profile may appeal to those seeking international diversification within the biotech and pharma services space. As with any equity investment, potential investors should conduct their own due diligence and consider how Lonza fits within their broader portfolio strategy.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.